In one study of prostate patients treated with specialized radiation therapy, 10-year biochemical disease-free survival
was 81% for low-risk, 78% for medium-risk, and just 62% for high-risk men, using identical criteria for success.
Table 2: Biochemical disease-free survival
for intermediate and high risk patients treated with a combination of HDR brachytherapy and external beam radiotherapy [Table omitted]
(37) (39) (38) Patients (n) 49 25 31 Follow-up (months, 64 47 30 mean) BDFS [years, n 34 (5%) 70 (4%) 87 (5%) (%)] Failure definition Phoenix Phoenix ASTRO Incontinence (%) 6 0 0 Patients with GU toxicity (%) Grade 1-2 12 NR NR Grade 3-4 14 16 NR Patients with GI toxicity (%) Grade 1-2 4 NR NR Grade 3-4 2 24 5 BDFS: biochemical disease-free survival
, ASRTO: American Society for Therapeutic Radiation and Oncology, GU: genitourinary, GI: gastrointestinal, NR: not reported.
Twelve-year biochemical disease-free survival
(bDFS) rates are 98% and 96% for low- and intermediate-risk disease.[sup.4,5] Sexual and overall quality of life (QOL) scores are better than prostatectomy with no worse bowel QOL.[sup.6] Investigators have reported that brachytherapy has better long-term control than external beam radiotherapy (EBRT) at median doses of 68 Gy (95 vs.